TCRT

Alaunos Therapeutics, Inc. NASDAQ Listed Aug 24, 2005

Healthcare ·Biotechnology ·US · alaunos.com

$2.69

After hrs $2.70 +2.66%

Mkt Cap $6.4M

52w Low $1.67 22.5% of range 52w High $6.20

50d MA $3.01 200d MA $2.91

P/E (TTM) -1.2x

EV/EBITDA -1.2x

P/B 2.4x

Debt/Equity 0.0x

ROE -194.0%

P/FCF -2.1x

RSI (14) —

ATR (14) —

Beta -1.13

50d MA $3.01

200d MA $2.91

Avg Volume 15.8K

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.

SIC Code

2834

CIK (SEC)

1107421

Phone

346 355 4099

8030 El Rio Street · Houston, TX 77054 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 31, 2026	AMC	-3.69	-0.40	+89.1%	2.86	+0.3%	+3.1%	-0.7%	-2.0%	+1.7%	-0.3%	—
Nov 14, 2025	AMC	-4.90	-0.55	+88.8%	2.97	+0.7%	+8.4%	+3.7%	-0.9%	+7.3%	-11.0%	—
Aug 14, 2025	AMC	-5.33	-0.63	+88.2%	2.40	+0.0%	-6.2%	+3.6%	-3.9%	-7.6%	-8.7%	—
May 15, 2025	AMC	-6.44	-0.67	+89.6%	2.82	+3.9%	+0.7%	-5.3%	-1.9%	-3.8%	+3.9%	—
Mar 31, 2025	AMC	-4.50	-0.46	+89.8%	1.47	-2.0%	+46.9%	+29.6%	+50.7%	-30.1%	+1.7%	—
Nov 14, 2024	AMC	-4.50	-0.70	+84.4%	2.34	+3.0%	-10.7%	+2.4%	-1.4%	+0.9%	+8.9%	—
Aug 14, 2024	AMC	-4.50	-0.71	+84.2%	2.42	+0.0%	-2.9%	-3.0%	-4.4%	+37.2%	-13.7%	—
May 15, 2024	AMC	-4.50	-1.10	+75.6%	11.90	-1.7%	+2.5%	-4.9%	-4.3%	-3.6%	+0.0%	—
Apr 2, 2024	AMC	-0.45	-0.49	-8.9%	17.60	-4.0%	+3.4%	-2.2%	-3.9%	-2.9%	+4.2%	—
Nov 14, 2023	AMC	-4.50	-6.00	-33.3%	11.15	-4.5%	+0.9%	-6.7%	-3.7%	+14.5%	-3.7%	—
Aug 14, 2023	AMC	-6.00	-6.00	+0.0%	59.04	-49.7%	-64.7%	+12.5%	-16.1%	-5.9%	+15.8%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Aug 15	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	$59.04	$29.70	-49.7%	-64.7%	+12.5%	-16.1%	-5.9%	+15.8%
Aug 14	Laidlaw & Co.	Downgrade	Buy → Hold	—	$59.99	$61.50	+2.5%	-1.6%	-64.7%	+12.5%	-16.1%	-5.9%
May 14	HC Wainwright & Co.	Upgrade	Neutral → Buy	—	—	—	—	—	—	—	—	—
May 3	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$73.91	$80.60	+9.1%	+12.7%	+36.0%	-17.1%	+10.2%	-1.4%
Nov 8	Raymond James	Maintains	Market Perform → Market Perform	—	$243.00	$240.00	-1.2%	+0.6%	-2.5%	-5.7%	+4.0%	-2.6%
Aug 9	Raymond James	Downgrade	Outperform → Market Perform	—	$340.50	$342.00	+0.4%	+0.9%	-16.2%	-2.1%	-0.5%	-4.8%
May 6	Raymond James	Maintains	Outperform → Outperform	—	$454.50	$451.50	-0.7%	-1.3%	+7.0%	-6.9%	+4.0%	-1.0%
Mar 11	Jefferies	Downgrade	Buy → Hold	—	$720.00	$735.00	+2.1%	+0.4%	-8.9%	-1.3%	-1.3%	-1.9%
Feb 28	HC Wainwright & Co.	Downgrade	Buy → Neutral	—	—	—	—	—	—	—	—	—
Mar 2	Raymond James	Maintains	Outperform → Outperform	—	$463.50	$468.00	+1.0%	+1.5%	-7.5%	+9.0%	-4.7%	+8.0%
Nov 14	Raymond James	Upgrade	Market Perform → Outperform	—	$405.00	$411.00	+1.5%	+0.0%	+14.1%	+3.9%	-4.1%	+1.0%
Jun 17	JP Morgan	Downgrade	Neutral → Underweight	—	—	—	—	—	—	—	—	—
Aug 9	Wells Fargo	Upgrade	Underperform → Market Perform	—	$730.50	$727.50	-0.4%	-0.2%	+5.8%	+1.4%	+4.8%	+7.3%
Jun 21	BMO Capital	Downgrade	Outperform → Market Perform	—	—	—	—	—	—	—	—	—
Mar 9	Mizuho	Downgrade	Buy → Neutral	—	$2007.00	$2016.00	+0.4%	+4.0%	-5.3%	-0.3%	-1.3%	+2.7%
Jan 13	BMO Capital	Upgrade	Underperform → Outperform	—	$889.50	$906.00	+1.9%	-3.2%	+54.5%	-10.1%	+1.8%	-6.0%
Mar 3	Piper Sandler	Upgrade	Underweight → Neutral	—	$639.00	$628.50	-1.6%	-1.2%	+5.7%	-0.2%	-2.7%	-1.9%
Mar 26	Brinson Patrick	Downgrade	Outperform → Market Perform	—	$769.50	$286.50	-62.8%	-64.5%	-5.5%	+6.4%	-3.8%	-3.4%
Mar 25	BMO Capital	Downgrade	Market Perform → Underperform	—	$727.50	$729.00	+0.2%	+5.8%	-64.5%	-5.5%	+6.4%	-3.8%
Mar 25	JP Morgan	Downgrade	Overweight → Neutral	—	$727.50	$729.00	+0.2%	+5.8%	-64.5%	-5.5%	+6.4%	-3.8%
Mar 25	Piper Sandler	Downgrade	Neutral → Underweight	—	$727.50	$729.00	+0.2%	+5.8%	-64.5%	-5.5%	+6.4%	-3.8%
Mar 25	Jefferies	Maintains	Hold → Hold	—	$727.50	$729.00	+0.2%	+5.8%	-64.5%	-5.5%	+6.4%	-3.8%
Dec 11	Jefferies	Downgrade	Buy → Hold	—	$613.50	$621.00	+1.2%	+8.6%	-6.1%	-1.7%	-0.5%	-0.2%
Mar 1	Jefferies	Maintains	Buy → Buy	—	$736.50	$736.50	+0.0%	-6.1%	+0.9%	+0.2%	+0.4%	+1.9%

Data updated apr 27, 2026 4:12am · Source: massive.com